Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
暂无分享,去创建一个
W. Eiermann | H. Rugo | I. C. Tudor | Y. Im | L. Fehrenbacher | Miguel Martín | R. Yerushalmi | J. Blum | J. Litton | S. Hurvitz | A. Gonçalves | A. Hannah | J. Ettl | Kyung-Hun Lee | H. Roché | D. Markova | R. Quek | L. Mina
[1] Paul Ellis,et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial , 2018, Nature Medicine.
[2] S. Loi,et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. , 2017, New England Journal of Medicine.
[3] David C. Smith,et al. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. , 2017, Cancer discovery.
[4] P. Fasching,et al. Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO). , 2017 .
[5] Alan Ashworth,et al. PARP inhibitors: Synthetic lethality in the clinic , 2017, Science.
[6] Y. Pommier,et al. Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib , 2013, Molecular Cancer Therapeutics.
[7] A. Ashworth,et al. BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency , 2013, Clinical Cancer Research.
[8] Y. Pommier,et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. , 2012, Cancer research.
[9] J. Lubiński,et al. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer , 2012, Breast Cancer Research.
[10] N. Curtin,et al. The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy , 2011, Therapeutic advances in medical oncology.
[11] Thomas Helleday,et al. The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings , 2011, Molecular oncology.
[12] S. Kaufmann,et al. PARP inhibition: PARP1 and beyond , 2010, Nature Reviews Cancer.
[13] D. Osoba,et al. Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[15] P. Armitage,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.
[16] J. Haybittle,et al. Repeated assessment of results in clinical trials of cancer treatment. , 1971, The British journal of radiology.